Joseph Martel
Ophthalmology · Pittsburgh, PANPI 1326247545
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,856 of the $2,770 with a category attached, or 67.0%. Argenx US, Inc. accounts for 71.4% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2024 at $2,539 and has fallen 99.2% since, to $21 in 2025.
Across 20 payments — averaging $138.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Argenx US, Inc.$2K
- Topcon Healthcare, Inc.$517
- Spark Therapeutics, Inc.$120
- Carl Zeiss Meditec, Inc.$70
- Alcon$65
- Astellas Pharma US Inc$21
Across 27 payments — averaging $210.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$4K
- Biogen$1K
What the payments were for
- Travel & lodging$1,85667%
- Food & beverage$91533%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Argenx US, Inc. | 11 | $1,977 |
| Topcon Healthcare, Inc. | 1 | $517 |
| Spark Therapeutics, Inc. | 4 | $120 |
| Carl Zeiss Meditec, Inc. | 1 | $70 |
| Alcon | 2 | $65 |
| Astellas Pharma US Inc | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VYVGART$1,523
How this compares
$2,770 in reported general payments places this provider in the 65th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 12 | $7,960 |
| Difluprednate | 22 | $6,106 |
| Prednisolone Acetate | 60 | $3,163 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 65 | $1,298 |
| Brimonidine Tartrate | 45 | $669 |
| Latanoprost | 54 | $385 |
| Dorzolamide Hcl | 17 | $279 |
| MoxifloxacinMoxifloxacin Hcl | 15 | $265 |
| Ketorolac Tromethamine | 17 | $192 |
| ErythromycinErythromycin Base | 16 | $181 |
| Timolol Maleate | 14 | $94 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Pittsburgh
- Francis MahPittsburgh$1.1M
- Robert NoeckerPittsburgh$632K
- Srinivas KondapalliPittsburgh$208K
- Deval ParanjpePittsburgh$121K
- Ian ConnerPittsburgh$82K
- Deepinder DhaliwalPittsburgh$65K
- Thomas FribergPittsburgh$55K
- Jenny YuPittsburgh$47K
- Vishal JhanjiPittsburgh$38K
- Omar AbbasiPittsburgh$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.